Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | APEX1 | P27695 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.30 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL977159 | 0.85 | MAP3K14 (0.38) | MAP3K14MEN1APEX1KMT2ATDP1 | |
| SCHEMBL3805680 | 0.84 | MAP3K14 (0.36) | MAP3K14MEN1APEX1KMT2ATDP1 | |
| SCHEMBL1332286 | 0.82 | NPC1 (0.36) | MAP3K14MEN1APEX1KMT2ATDP1 | |
| SCHEMBL10488014 | 0.82 | MAP3K14 (0.35) | MAP3K14MEN1APEX1KMT2ATDP1 | |
| SCHEMBL11095324 | 0.82 | NPC1 (0.36) | MAP3K14MEN1APEX1KMT2ATDP1 | |
| SCHEMBL9468465 | 0.82 | MAP3K14 (0.35) | MAP3K14MEN1APEX1KMT2ATDP1 | |
| SCHEMBL20589363 | 0.81 | PRKCA (0.38) | MAP3K14MEN1APEX1KMT2ATDP1 | |
| SCHEMBL6551912 | 0.79 | HSD17B10 (0.39) | — | |
| SCHEMBL13386960 | 0.78 | MAP3K14 (0.32) | MAP3K14 | |
| SCHEMBL7264550 | 0.77 | MAP3K14 (0.40) | MAP3K14MEN1APEX1KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260027147-A1 | EXTRACELLULAR VESICLE-ASO CONSTRUCTS TARGETING CEBP/BETA | LONZA SALES AG (CH) | 2026-01-29 | — | — | US | disclosed |
| US-20250382613-A1 | METHODS OF USING EXTRACELLULAR VESICLE-ASO TARGETING STAT6 | LONZA SALES AG (CH) | 2025-12-18 | — | — | US | disclosed |
| EP-4562156-A2 | EXTRACELLULAR VESICLE-ASO CONSTRUCTS TARGETING CEBP/BETA | Lonza Sales AG (CH) | 2025-06-04 | — | — | EP | disclosed |
| CN-114728078-B | Extracellular vesicles linked to molecules and uses thereof | 隆萨销售股份公司 | 2025-05-16 | — | — | CN | disclosed |
| EP-4547259-A2 | METHODS OF USING EXTRACELLULAR VESICLE-ASO TARGETING STAT6 | Lonza Sales AG (CH) | 2025-05-07 | — | — | EP | disclosed |
| CN-119948163-A | CEBP/beta targeted extracellular vesicle-ASO constructs | 隆萨销售股份有限公司 | 2025-05-06 | — | — | CN | disclosed |
| CN-119855597-A | Methods of using STAT 6-targeted extracellular vesicles-ASOs | 隆萨销售股份有限公司 | 2025-04-18 | — | — | CN | disclosed |
| US-20250115904-A1 | EXTRACELLULAR VESICLE-ASO CONSTRUCTS TARGETING STAT6 | LONZA SALES AG (CH) | 2025-04-10 | — | — | US | disclosed |
| EP-4470619-A2 | EXTRACELLULAR VESICLE-ASO CONSTRUCTS TARGETING STAT6 | Lonza Sales AG (CH) | 2024-12-04 | — | — | EP | disclosed |
| US-20240254481-A1 | EXTRACELLULAR VESICLE-ASO CONSTRUCTS TARGETING STAT6 | LONZA SALES AG (CH) | 2024-08-01 | — | — | US | disclosed |
| US-20110111501-A1 | COMPLEX OF POLYSACCHARIDE AND DOUBLE-STRANDED RNA | NAPA JENOMICS CO., LTD. (JP) | 2011-05-12 | — | — | US | disclosed |
| US-20110034545-A1 | DOUBLE-STRANDED LIPID-MODIFIED RNA HAVING HIGH RNA INTERFERENCE EFFECT | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-02-10 | — | — | US | disclosed |
| EP-2264167-A1 | DOUBLE-STRANDED LIPID-MODIFIED RNA HAVING HIGH RNA INTERFERENCE EFFECT | National Institute of Advanced Industrial Science and Technology (JP) | 2010-12-22 | — | — | EP | disclosed |
| US-20100298411-A1 | LIPID-MODIFIED DOUBLE-STRANDED RNA HAVING POTENT RNA INTERFERENCE EFFECT | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY | 2010-11-25 | — | — | US | disclosed |
| EP-2226384-A1 | COMPLEX OF POLYSACCHARIDE AND DOUBLE-STRANDED RNA | National Institute of Advanced Industrial Science and Technology (JP) | 2010-09-08 | — | — | EP | disclosed |
| EP-2217284-A2 | LIPID-MODIFIED DOUBLE-STRANDED RNA HAVING POTENT RNA INTERFERENCE EFFECT | National Institute of Advanced Industrial Science And Technology (JP) | 2010-08-18 | — | — | EP | disclosed |
| WO-2009054551-A2 | LIPID-MODIFIED DOUBLE-STRANDED RNA HAVING POTENT RNA INTERFERENCE EFFECT | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 2009-04-30 | — | — | WO | disclosed |
| US-20080071068-A1 | Cytoplasmic Localization Dna and Rna | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 2008-03-20 | — | — | US | disclosed |
| EP-1731615-A1 | CYTOPLASMIC LOCALIZATION DNA AND RNA | National Institute of Advanced Industrial Science and Technology (JP) | 2006-12-13 | — | — | EP | disclosed |
| US-6160128-A | Tritioacetylating reagents and processes for preparation thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-12-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250115904-A1 | EXTRACELLULAR VESICLE-ASO CONSTRUCTS TARGETING STAT6 | STAT6, STAT1, STAT5B | MAP3K14 2083/4885MEN1 3824/4885APEX1 3064/4885 |
| US-20250382613-A1 | METHODS OF USING EXTRACELLULAR VESICLE-ASO TARGETING STAT6 | STAT6, EXOSC5, STAT5B | MAP3K14 2250/4885MEN1 3833/4885APEX1 3264/4885 |
| US-20260027147-A1 | EXTRACELLULAR VESICLE-ASO CONSTRUCTS TARGETING CEBP/BETA | CEBPZ, OSBP, DIS3 | MAP3K14 3974/4885MEN1 4660/4885APEX1 1818/4885 |
| US-20100298411-A1 | LIPID-MODIFIED DOUBLE-STRANDED RNA HAVING POTENT RNA INTERFERENCE EFFECT | NSUN3, NSUN2, RNASE1 | MAP3K14 4576/4885MEN1 3862/4885APEX1 392/4885 |
| US-20080071068-A1 | Cytoplasmic Localization Dna and Rna | HNRNPH3, HNRNPUL2, HNRNPUL1 | MAP3K14 3824/4885MEN1 2649/4885APEX1 546/4885 |
| US-20110034545-A1 | DOUBLE-STRANDED LIPID-MODIFIED RNA HAVING HIGH RNA INTERFERENCE EFFECT | NSUN3, NSUN2, ADAR | MAP3K14 4613/4885MEN1 4037/4885APEX1 418/4885 |
| US-20110111501-A1 | COMPLEX OF POLYSACCHARIDE AND DOUBLE-STRANDED RNA | RNGTT, MAN2A1, ADAR | MAP3K14 4014/4885MEN1 2885/4885APEX1 1001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.